SCHEMBL486303

SCHEMBL486303

O=C(Cl)c1cncc(Br)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.67
HCAR2 Q8TDS4 1/20 0.67
KDM4E B2RXH2 1/20 0.58
HTT P42858 4/20 0.56
ALOX15 P16050 1/20 0.56
RAB9A P51151 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
ROCK2 O75116 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
ALOX12 P18054 1/20 0.50
ROCK1 Q13464 1/20 0.50
MAPT P10636 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
EGFR P00533 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SMYD3 Q9H7B4 1/20 0.45
CASP3 P42574 1/20 0.45
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29597600 1.00 POLB (0.67) POLBHCAR2KDM4EHTTALOX15
Hydrochloric Acid SCHEMBL3050677 0.98 POLB (0.64) POLBHCAR2KDM4EHTTALOX15
SCHEMBL2268149 0.84 HCAR2 (0.48) POLBHCAR2KDM4EHTTALOX15
SCHEMBL22569116 0.82 HTT (0.78) POLBHCAR2KDM4EHTTALOX15
SCHEMBL112388 0.80 HCAR2 (1.00) POLBHCAR2KDM4EHTTALOX15
SCHEMBL29603529 0.80 HCAR2 (1.00) POLBHCAR2KDM4EHTTALOX15
SCHEMBL28801075 0.80 POLB (0.69) POLBHCAR2KDM4EHTTALOX15
SCHEMBL578591 0.78 POLB (0.67) POLBHCAR2KDM4EHTTALOX15
SCHEMBL10461109 0.78 HCAR2 (0.96) POLBHCAR2KDM4EHTTALOX15
SCHEMBL5839508 0.78 POLB (0.67) POLBHCAR2KDM4EHTTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111116580-B Improved preparation method of nicergoline 上海应用技术大学 2022-08-23 CN claimed
CN-113480532-B Synthesis method of nicergoline 福安药业集团重庆博圣制药有限公司 2022-08-16 CN claimed
CN-113480532-A Synthesis method of nicergoline 福安药业集团重庆博圣制药有限公司 2021-10-08 CN claimed
CN-104262246-A 5-phenylnicotinamide Bcr-Abl inhibitors as well as preparation method and application thereof UNIV XI AN JIAOTONG 2015-01-07 CN claimed
CN-102276524-B Preparation method of substituted picolinamide compounds UNIV EASTERN LIAONING 2014-03-05 CN claimed
CN-103159756-A Novel preparation method for nicergoline SHANDONG FANGMING PHARM GROUP 2013-06-19 CN claimed
CN-102718761-A Preparation method for nicergoline ZHUHAI RUNDU PHARMACEUTICAL CO LTD 2012-10-10 CN claimed
CN-102276524-A Substituted picolinamide compounds and preparation method thereof 2011-12-14 CN claimed
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 EP disclosed
US-20250230144-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-07-17 US disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
US-12110279-B2 Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2024-10-08 US disclosed
CN-118480001-A C-Kit (V559D)/PDGFR beta double-target allosteric inhibitor and preparation method, pharmaceutical composition and application thereof 贵州省天然产物研究中心 2024-08-13 CN disclosed
US-4753949-A IMPROVES COGNITIVE FUNCTION, CALCIUM ANTAGONIST RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1988-06-28 US disclosed
EP-0251652-A2 t-Butyl ergoline derivatives FARMITALIA CARLO ERBA S.r.l. (IT) 1988-01-07 EP disclosed
CN-86104086-A The preparation method of 2-halogen nicergoline derivatives and its acid salt and new 2-halogen Varson class 1986-12-17 CN disclosed
WO-1986006628-A1 BENZAMIDE AND NICOTINAMIDE RADIOSENSITIZERS SRI INTERNATIONAL (US) 1986-11-20 WO disclosed
EP-0198311-A2 Nicotin amides and their use as fungicidal agents F. HOFFMANN-LA ROCHE AG (CH) 1986-10-22 EP disclosed
EP-0192976-A1 Compounds having antihyperlipemic activity, processes for the preparation thereof and pharmaceutical compositions containing them BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) 1986-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230144-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS KCNJ4, KCNK4, KCNQ4 POLB 4491/4885HCAR2 1924/4885KDM4E 882/4885
US-12110279-B2 Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same VAPB, VAPA, FABP1 POLB 2759/4885HCAR2 2481/4885KDM4E 4371/4885
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 POLB 849/4885HCAR2 4800/4885KDM4E 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.